A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
A Phase 3b, Multicenter, Open-label, Single-arm Trial to Evaluate the Efficacy and Safety of Orally Administered Centanafadine QD XR Capsules in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: otsuka-professionalservices@otsuka-us.com
연구 장소
-
-
Florida
-
Gainesville, Florida, 미국, 32607
- 모병
- Sarkis Clinical Trials - Gainesville
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
수석 연구원:
- Sarkis
-
Jacksonville, Florida, 미국, 32256
- 모병
- CNS Healthcare - Jacksonville (Clinical Neuroscience Solutions - Jacksonville)
-
수석 연구원:
- Jones
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
Maitland, Florida, 미국, 32751
- 모병
- Accel Research Sites-Maitland
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
수석 연구원:
- Marraffino
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70125
- 모병
- Nola Research Works
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
수석 연구원:
- Hebert
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02132
- 모병
- Boston Clinical Trials
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
수석 연구원:
- Mezhebovsky
-
Watertown, Massachusetts, 미국, 02472
- 모병
- Adams Clinical - Watertown
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
수석 연구원:
- Rutrick
-
-
Missouri
-
Saint Charles, Missouri, 미국, 63304
- 모병
- St. Charles Psychiatric Associates/Midwest Research Group
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
수석 연구원:
- Mattingly
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89128
- 모병
- Center for Psychiatry and Behavioral Medicine. Inc.
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
수석 연구원:
- Childress
-
-
New Jersey
-
Cherry Hill, New Jersey, 미국, 08002
- 모병
- Center for Emotional Fitness
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
수석 연구원:
- Corcoran
-
-
New York
-
New York, New York, 미국, 10128
- 모병
- The Medical Research Network, LLC
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
수석 연구원:
- Careri
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45215
- 모병
- Patient Priority Clinical Trials
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
수석 연구원:
- Popovitz
-
-
Oregon
-
Portland, Oregon, 미국, 97210
- 모병
- Summit Research Network
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
수석 연구원:
- Essink
-
-
Texas
-
Austin, Texas, 미국, 78737
- 모병
- Donald J. Garcia, Jr, MD, PA
-
수석 연구원:
- Garcia
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
Bellaire, Texas, 미국, 77401
- 모병
- Houston Clinical Trials LLC
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
수석 연구원:
- Katic
-
Houston, Texas, 미국, 77089
- 모병
- Kaleidoscope Clinical Research
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
수석 연구원:
- Higgins
-
-
Washington
-
Everett, Washington, 미국, 98201
- 모병
- Core Clinical Research
-
연락하다:
- Otsuka Call Center
- 전화번호: 844-687-8522
- 이메일: Otsuka-ProfessionalServices@otsuka-us.com
-
수석 연구원:
- Knutson
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria
- Primary diagnosis of ADHD per the Adult ADHD Clinical Diagnostic Scale (ACDS).
- Adult ADHD Investigator Symptom Rating Scale (AISRS) total score of ≥ 28 at baseline.
- Symptoms of ED as determined by the WRAADDS-ED subscale score ≥ 7 at baseline.
- CGI-S-ADHD rating ≥ 4 (at least moderate severity) at baseline.
Exclusion Criteria
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for a lifetime diagnosis of bipolar and related disorders, schizophrenia spectrum and other psychotic disorders, borderline and antisocial personality disorders, neurocognitive disorders, autism spectrum disorder, or intellectual disability.
- DSM-5 criteria for a current diagnosis of major depressive disorder, post-traumatic stress disorder, any substance use disorder, untreated/unstable obstructive sleep apnea, eating disorders, or obsessive compulsive disorder.
- Any other current DSM-5 comorbid psychiatric disorder identified by the Mini International Neuropsychiatric Interview (MINI) or any medical condition that, in the judgment of the investigator, could be expected to require treatment with medications prohibited in this trial that cannot be safely discontinued with completion of an appropriate washout, could confound efficacy or safety assessments, or be the primary driver of ED.
- Presence of an unstable or uncontrolled medical condition that, in the opinion of the investigator, could pose a safety risk to the participant or could manifest with psychiatric symptoms (eg, thyroid disease).
- In the clinical opinion of the investigator, the participant has not derived significant therapeutic benefit from 2 or more ADHD therapies of 2 different classes (eg, amphetamine and methylphenidate, or amphetamine and atomoxetine) given with an acceptable dose and duration during adulthood (aged 18 years or older).
- Current use of prohibited psychotropic medications that cannot be discontinued within 7 to 28 days prior to enrollment.
- Any disorder that is the primary focus of treatment other than ADHD.
- Evidence of current substance use disorder or history in the past 12 months.
- History of any prior exposure to centanafadine.
- Participated in other clinical trials involving investigational drugs within 180 days prior to screening or participated in more than 2 interventional clinical trials involving investigational drugs within the past year.
- Have an allergy to the IMP or any component of the IMP.
Note: Other protocol-specified inclusion/exclusion criteria may apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Centanafadine XR
Participants will receive centanafadine XR capsule 328.8 milligrams (mg), orally, QD, for 8 weeks. |
Oral capsules
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Change From Baseline to Week 8 in the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) Total Score
기간: Baseline up to Week 8
|
Baseline up to Week 8
|
2차 결과 측정
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Change From Baseline to Week 8 in the Wender-Reimherr Adult Attention Deficit Disorder Scale Emotional Dysregulation (WRAADDS-ED) Subscale Score
기간: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Clinical Global Impressions-Severity Scale for Attention-Deficit/Hyperactivity Disorder (CGI-S-ADHD) Score
기간: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) T-score for the Global Executive Composite (GEC) Scale
기간: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the BRIEF-A T-score for the Behavioral Regulation Index (BRI) Scale
기간: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the BRIEF-A T-score for the Metacognition Index (MI) Scale
기간: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Difficulties in Emotion Regulation Scale (DERS) Total Score
기간: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Nonacceptance of Emotional Responses (NONACCEPT) DERS Subscale Score
기간: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Difficulties Engaging in Goal-Directed Behavior (GOALS) DERS Subscale Score
기간: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Impulse Control Difficulties (IMPULSE) DERS Subscale Score
기간: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Lack of Emotional Awareness (AWARE) DERS Subscale Score
기간: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Limited Access to Emotion Regulation Strategies (STRATEGIES) DERS Subscale Score
기간: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Lack of Emotional Clarity (CLARITY) DERS Subscale Score
기간: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Attention-Deficit/Hyperactivity Disorder Symptoms, Executive Function Deficits, and Emotional Dyscontrol as Assessed by the Adult ADHD Self-Report Scale (ASRS) Score
기간: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Number of Participants With Adverse Events
기간: Up to Week 9
|
Up to Week 9
|
|
Number of Participants With Suicidal Ideation or Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
기간: Up to Week 9
|
Up to Week 9
|
공동 작업자 및 조사자
스폰서
스폰서
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 405-201-00231
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
IPD 공유 기간
Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
IPD 공유 액세스 기준
Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .